The CPDR mission is fulfilled primarily through its three principal programs – the Clinical Research Program, the Basic Science Research Program and the Multicenter National Prostate Cancer Database – and through a robust education and training program that operates out of its Headquarters location, the Clinical Research Center, and the original laboratories at USUHS. CPDR is also committed to patient outreach, primarily through its affiliation with the WRAMC US TOO! organization and through a heavy schedule of health fairs in which it participates.

To get started, find your selected interest to the right, or use the blue navigation bar above.

2009 Cancer Statistics  Source: American Cancer Society

2009 State-by-State CaP Statistics  Source: Zerocancer.org

> NEWS

2010 Internship Program Immerses Minority Students in Prostate Cancer Research

August 31, 2010

Five interns were selected for the 2010 program based on academic achievements at UDC in prostate cancer research. CPDR provided a structured framework for the program, offering a rich multi-disciplinary prostate cancer translational research environment that is credited for landmark discoveries. The students completed their program by presenting their training and research accomplishments at USU to leaders from the participating organizations. Dr. Taduru Sreenath, CPDR assistant director, served as the primary coordinator for the program...

Read Full News Release

Scientists develop highly specific ERG monoclonal antibody for detecting common oncogenic alterations in prostate cancer.

June 29, 2010

Bethesda, Maryland--Researchers at the Uniformed Services University of the Health Sciences (USU) Center for Prostate Disease Research (CPDR), in collaboration with investigators at the Armed Forces Institute of Pathology and Walter Reed Army Medical Center have developed a highly specific assay for the detection of ERG oncoprotein that is regulated by prevalent gene fusions present in over half of all prostate cancers. These findings are reported in the advanced online publication of Prostate Cancer and Prostatic Diseases (Nature Publishing Group, June 29), “ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.”

ERG Oncoprotein

“We are excited about the potential of streamlining the detection of ERG oncoprotein in clinical specimens”

-- Dr. Shiv Srivastava, CPDR Scientific Director

PCAN Journal Article

USU News Release